Breakthrough Study Shows that Dexcom G5 Mobile CGM Outperforms Abbott FreeStyle Libre FGM in Reducing Hypoglycaemia

Randomised controlled trial (RCT) assessed impact of two glucose monitoring systems on hypoglycaemia in people with type 1 diabetes EDINBURGH, Scotland, Jan. 30, 2018 /PRNewswire/ -- DexCom, Inc. (Nasdaq: DXCM), announced today the publication of a novel head-to-head study that...

from PR Newswire: //http://ift.tt/2nqsBjE